pubrio
Bioceltix logo

Bioceltix

Privately Held
bioceltix.com
バイオテクノロジー研究32 employeesFounded 2017🇵🇱 ポーランド

Bioceltix is a Wrocław-based and internationally oriented biotechnological company developing innovative, both stem cells and secretome based products, for companion animals. Our flagship technology for manufacturing biopharmaceuticals for veterinary use utilizes the therapeutic potential of allogeneic stem cells (one donor – many recipients). Owning a GMP production facility, we provide single technology for several species, diseases, and routes of administration. Our cutting-edge approach will allow the product to be batch-produced and ready for off-the-shelf sale. The veterinary medicines, based on the immunomodulatory mechanism of action of MSC, will be an alternative to the symptomatic pharmacotherapy focused mainly on alleviating pain and inflammation. Our goal is to create analgesic and anti-inflammatory biopharmaceuticals that will induce the natural mechanisms of regenerating tissues affected by the disease. In our pipeline we have products intended for the treatment of atopic dermatitis and osteoarthritis in dogs and of osteoarthritis in horses – all in the advanced development stage. The registration procedure for BCX-CM-J and BCX-EM in the European Medicines Agency has been launched. We are led by the motto: “More than animal. More than technology.”

設立年
2017
従業員数
32
業種
バイオテクノロジー研究
企業タイプ
Privately Held
本社
🇵🇱Wrocław, Woj. Dolnośląskie (+1)
専門分野
リサーチ製薬バイオテクノロジー動物健康バイオテクノロジー研究

拡大インテリジェンス

NEW · Pubrio 限定

Bioceltix の市場拡大を追跡しています

グローバル展開

ライブ
ステージ
検討中投資中参入中稼働中
知っておきたい情報

Bioceltix に関するよくある質問

Bioceltix の事業、市場、成長シグナルに関する簡潔な回答。

Bioceltix is a Wrocław-based and internationally oriented biotechnological company developing innovative, both stem cells and secretome based products, for companion animals. Our flagship technology for manufacturing biopharmaceuticals for veterinary use utilizes the therapeutic potential of allogeneic stem cells (one donor – many recipients). Owning a GMP production facility, we provide single technology for several species, diseases, and routes of administration. Our cutting-edge approach will allow the product to be batch-produced and ready for off-the-shelf sale. The veterinary medicines, based on the immunomodulatory mechanism of action of MSC, will be an alternative to the symptomatic pharmacotherapy focused mainly on alleviating pain and inflammation. Our goal is to create analgesic and anti-inflammatory biopharmaceuticals that will induce the natural mechanisms of regenerating tissues affected by the disease. In our pipeline we have products intended for the treatment of atopic dermatitis and osteoarthritis in dogs and of osteoarthritis in horses – all in the advanced development stage. The registration procedure for BCX-CM-J and BCX-EM in the European Medicines Agency has been launched. We are led by the motto: “More than animal. More than technology.”

今日から旅を始めましょう

まずはプラットフォームでも、まずは会話からでも

Pubrio を自分で使うことも、リサーチ・リード獲得・データ連携を私たちに任せることもできます。

チームに相談
Start Journey Image
pubrio

Pubrio は 50 以上のローカルソースからビジネス・人物・インテントデータを統合し、AI と収益チームに市場全体の可視性を提供します。

© 2026 Pubrio. 無断転載を禁じます。